---
title: Mendelian Randomization in Practice
subtitle: AFGen Consortium Fellows Meeting
author: Anish S. Shah, MD, MS
institute: Division of Cardiology, Department of Medicine, University of Illinois Chicago 
date: April 24, 2024
format:
  revealjs:
    transition: fade
    transition-speed: fast
    slide-number: true
    incremental: true
    auto-animate-easing: ease-in-out
    auto-animate-unmatched: false
    progress: true
    chalkboard: true
    height: 1080
    width: 1920

revealjs-plugins:
  - attribution

csl: ../../apa.csl
---

# Introduction

---

::: {.callout-important title="Paper"}
Björnson, Elias, Martin Adiels, Marja-Riitta Taskinen, Stephen Burgess, M. John Chapman, Chris J. Packard, and Jan Borén. 
[Lipoprotein(a) Is Markedly More Atherogenic Than LDL: An Apolipoprotein B-Based Genetic Analysis]{.orange}
Journal of the American College of Cardiology 83, no. 3 (January 23, 2024): 385–95. 
https://doi.org/10.1016/j.jacc.2023.10.039.
:::

. . .

:::: {.columns}
::: {.column width="50%"}
Question:

- Are Lp(a) and LDL equivalent in their atherogenicity?
:::
::: {.column width="50%"}
Approach:

- Using ApoB as a quantification of particles, assess genetic contribution to Lp(a) and LDL and the subsequent CVD risk
:::
::::


## Objectives

a. Review the role of lipids in atherosclerosis
a. Understand the effect of genetic variants on lipid particles
a. Describe the principles of mendelian randomization
a. Consider the intersection of epidemiology/causality using this methodology

## Outline

1. An overview of lipids
  a. Lipid molecules and density
  a. Structure of Lp(a)
1. (Re)-introduction to mendelian randomization
1. Review of the findings from the paper by @Bjornson2024

# Lipids

## Basics of lipids

:::: {.columns}
::: {.column width="35%"}

::: {.fragment fragment-index=1}
::: {.fragment .highlight-current-red fragment-index=4}
Cholesterol
:::
:::

::: {.fragment fragment-index=2}
Triglycerides
:::

:::
::: {.column width="65%"}

::: {.fragment fragment-index=3}
::: {.fragment .highlight-current-red fragment-index=4}
High-density lipoprotein (HDL)  
Low-density lipoprotein (LDL)  
Very low-density lipoprotein (VLDL)  
:::
:::

:::
::::

::: {.fragment fragment-index=5}
Cholesterols (and triglycerides) are insoluble in water, and must be transported via protein structures called [lipoproteins]{.red}.
:::

---

![Diagram of structure of a lipoprotein particle](cleveland-clinic-lipoprotein.png){#fig-lipoprotein}

::: attribution
https://my.clevelandclinic.org/health/articles/23229-lipoprotein
:::

## Lipoprotein classification

- Lipoproteins have a core of cholesterol esters and triglycerides
- Lipoproteins are surrounded by phospholipid layer which contain [apolipoproteins]{.orange}
- HDL, usually < 12 nm in size, contain apolipoprotein A1
- LDL, usually 18-25 nm in size, contain apolipoprotein B100
- IDL is < 50 nm and VLDL > 50 nm are similar to LDL, except do not enter arterial intima

. . .

::: {.callout-important}
Each LDL (including IDL & VLDL) contain only [one ApoB100 protein]{.orange}
:::

---

![Classification of cholesterol types](holmes-2019-cholesterol-types.png){#fig-cholesterol}

::: attribution
@Holmes2019
:::

## What is lipoprotein(a)?

. . . 

Lp(a) is a type of LDL particle

. . .

Contains an additional protein called apolipoprotein (a), which binds directly to ApoB100 via a *disulfide bond*

. . .

::: {.fragment .highlight-current-red}
This means that Apo(a) and ApoB100 exist in a 1:1 molar ratio
:::

# Mendelian Randomization

## Basic concepts

## Types of MR

- One-sample v. two-sample

::: attribution
@Sanderson2022
:::

---

![Comparison of MR and RCT approaches](sanderson-2022-mr-rct.png){#fig-mr-rct}

::: attribution
@Sanderson2022
:::

# Findings

---

![Relative atherogenicity of Lp(a) and LDL particles](bjornson-2024-central-illustration.png){#fig-central}

::: attribution
@Bjornson2024
:::

---

![Effect of SNP clusters on plasma apoB and Lp(a) levels](bjornson-2024-snp-clusters-lpa.png){#fig-snp}

::: attribution
@Bjornson2024
:::

---

![Relationship of CHD risk to apoB from LDL and Lp(a)](bjornson-2024-chd-risk-by-apob-type.png){#fig-chd}

::: attribution
@Bjornson2024
:::

---

![Odds for CVD by genetic prediction of variation in apoB](bjornson-2024-odds-ratio.png){#fig-odds}

::: attribution
@Bjornson2024
:::

---

![Relative atherogenicity of Lp(a) and LDL associated apoB](bjornson-2024-relative-atherogenicity.png){#fig-relative}

::: attribution
@Bjornson2024
:::

---

![ApoB and CHD risk by polygenic scores](bjornson-2024-chd-risk-pgs.png){#fig-pgs}

::: attribution
@Bjornson2024
:::

## References {.smallest}

::: {#refs}
:::
